Targeting SIRPα as a therapeutic strategy for the treatment of breast cancer brain metastasis

Jessica Mackert, PhD, Elizabeth Stirling, PhD, Steven Bronson, DVM, Adam Wilson, Mitra Kooshki, MS, Dawen Zhao, MD/PhD, Pierre Triozzi, MD, Glenn Lesser, MD, David Soto-Pantoja, PhD

Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer characterized by the lack of specific targets and an incidence of brain metastasis from the primary site of approximately 35%. There is no standard treatment for managing brain metastasis associated with TNBC; therefore, new strategies are urgently needed to overcome disease mortality. The CD47/SIRPα signaling pathway is implicated in tumor progression due to bypassing innate and adaptive immune surveillance. Most strategies targeting this pathway focus on targeting the receptor CD47; however, targeting SIRPα as a potential strategy to mitigate tumor burden remains understudied. Analysis of gene expression database shows that SIRPα expression is significantly elevated in invasive breast cancer compared to primary. Furthermore, single-cell data indicates that SIRPα is expressed in basal epithelial cells in TNBC tumors, aside from the myeloid compartment. Our immune staining against SIRPα in breast cancer patient biopsies shows a 3.5-fold increase in SIRPα expression in metastatic lesions compared to the primary tumor (n=19; p ≤ 0.01). To confirm that SIRPα is expressed on triple-negative cancer cells and whether it may be increased in brain metastatic cells, we stained 4T1 parental and brain-trophic 4T1-Br3 cells and found an 84% increase in SIRPα in the metastatic cells (n=3; p ≤ 0.05). Furthermore, Agilent xCELLigence Real-Time Cell Analysis revealed that SIRPα blockade inhibits brain-trophic 4T1br3 cell migration (n=4; ps0.01). Therefore, targeting SIRPα may be a new immunotherapeutic strategy to treat TNBC brain metastasis. Anti-SIRPα treatment of mice bearing brain-trophic 4T1br3 orthotopic tumors showed reduced tumor volume and tumor weight by over 50% compared to isotype control-treated mice (n=6; p ≤ 0.05). Furthermore, in a model of intracardial brain metastasis, treatment with SIRPα antibody was associated with a 40% increase in survival on day 15 compared to isotype control-treated mice. SIRPα blockade also reduced metastatic brain lesion formation by approximately 90%, determined by IVIS imaging (n=4-7; p ≤ 0.05). Nanostring GeoMX digital spatial profiling of the brain lesions revealed the immune checkpoints cluster of differentiation 152 (CTLA4), programmed cell death protein 1 (PD-1), programmed death ligand-1 (PD-L1), and cluster of differentiation 276 (CD276 or B7-H3) were significantly reduced in SIRPα treated brain lesions (n=3-6; p ≤ 0.05). Additionally, the extracellular matrix protein fibronectin, which contributes to invasion, metastasis, and immune evasion, was reduced by 70% in SIRPα treated brain lesions (n=3-6; p ≤ 0.05). These data suggest that SIRPα blockade may influence tumor and innate immune cells to limit brain metastatic breast cancer growth and enhance survival.